Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuzi Guizhi prescription is a Traditional Chinese Medicine (TCM) herbal formulation developed by the Yunnan Hospital of Traditional Chinese Medicine for the treatment of ankylosing spondylitis (AS). The prescription is specifically tailored for patients diagnosed with the "kidney deficiency and supervisory cold" (Shenxu Duhan) pattern, a TCM classification characterized by spinal stiffness and pain exacerbated by cold. The formulation typically centers on the synergistic combination of *Aconiti Lateralis Radix Praeparata* (Fuzi) and *Cinnamomi Ramulus* (Guizhi), which are traditionally used to warm the kidneys, dispel pathogenic cold, and unblock the Du meridian (supervisory vessel). In clinical settings, such as the trial ChiCTR2400085040, it is evaluated as an adjunctive therapy to standard care and functional exercise, with a focus on improving ASAS20 response rates and modulating systemic inflammatory markers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fuzi guizhi prescription.